Cardio Diagnostics Holdings received a notice from Nasdaq on June 3, 2024, indicating non-compliance with the minimum bid price requirement, as its common stock has traded below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period until December 2, 2024, to regain compliance.The company can regain compliance if its stock price closes at or above $1.00 for a minimum of ten consecutive business days before the deadline. If unsuccessful, Cardio Diagnostics may be eligible for an additional 180-day compliance period, provided it meets other Nasdaq Capital Market listing requirements and submits a written intention to cure the deficiency.The company is actively monitoring its stock price and considering all available options to regain compliance, including the possibility of a reverse stock split. The notice has no immediate effect on the listing or trading of the company's common stock and warrants on the Nasdaq Capital Market.

Cardio Diagnostics Holdings received a notice from Nasdaq on June 3, 2024, indicating non-compliance with the minimum bid price requirement, as its common stock has traded below $1.00 for 30 consecutive business days. The company has been granted a 180-day compliance period until December 2, 2024, to regain compliance.The company can regain compliance if its stock price closes at or above $1.00 for a minimum of ten consecutive business days before the deadline. If unsuccessful, Cardio Diagnostics may be eligible for an additional 180-day compliance period, provided it meets other Nasdaq Capital Market listing requirements and submits a written intention to cure the deficiency.The company is actively monitoring its stock price and considering all available options to regain compliance, including the possibility of a reverse stock split. The notice has no immediate effect on the listing or trading of the company's common stock and warrants on the Nasdaq Capital Market.